Table 1 Patients’ characteristics
From: SARS-CoV-2 detection in the lower respiratory tract of invasively ventilated ARDS patients
Patients (N = 90) | |
|---|---|
French center (versus Swiss center), n (%) | 42 (46.7) |
Age, median [IQR] | 62.5 [54; 70] |
Sex, n (%) | |
Male | 71 (78.9) |
BMI, median [IQR] | 29.6 [26; 33.3] |
SAPS II at ICU admission, median [IQR] | 45.5 [37; 61] |
SOFA at ICU admission, median [IQR] | 7 [6; 10] |
Comorbidities | |
Cardiovascular, n (%) | 36 (40) |
Chronic respiratory failure, n (%) | 18 (20) |
Renal failure, n (%) | 14 (15.6) |
Immunosuppression, n (%) | 28 (31.1) |
Diabetes mellitus, n (%) | 27 (30) |
Cancer, n (%) | 4 (4.4) |
Treatment administered | |
Ritonavir/lopinavir, n (%) | 38 (42.2) |
Remdesivir, n (%) | 8 (8.9) |
Hydroxychloroquine, n (%) | 27 (30) |
Tocilizumab, n (%) | 8 (8.9) |
Corticosteroids, n (%) | 48 (53.3) |
Number of different antibiotics utilized (per patient), median [IQR] | 7 [4; 10] |
Number of bacteremia per patient, mean (SD) | 0.80 (3.92) |
Number of VAP per patient, mean (SD) | 0.92 (1.05) |
Number of LRTS per patient, median [IQR] | 3 [2; 4] |
Viral load (log10 copies per mL), median [IQR] | 3.3 [1.8; 5.2] |
Time to negativity in LRTS, median [IQR] | 29 [23; 34] |
Mortality 6 weeks, n (%) | 23 (25.6) |